Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

987 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-03-31

Study Completion Date

2017-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a national, multicenter, cross-sectional, observational study within a convenience sample of Internal Medicine departments from 100 hospitals in Spain which agree to participate in the study. This study will be a cross-sectional chart review which will require the collection of data from medical records and from face-to-face interviews conducted during the inclusion visit. Physician interviews are needed to collect three variables of interest, recommended by the Spanish Society of Internal Medicine as necessary data about profile and management of NVAF patients: cognitive deterioration based on the patient's responses, physician's assessment of the patient's life expectancy, and physician's opinion of the antithrombotic treatment previously prescribed. The investigators will only provide their opinion on previously prescribed therapies (i.e. prescribed before F2F). Hospitals to be contacted for the study include those known to participate in observational studies in Spain; the hospitals will therefore not be a random sample of Spanish hospitals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Atherosclerosis in Atrial Fibrillation

NCT01882114

Atrial Fibrillation Metabolic Syndrome Oxidative Stress +2 more

UNKNOWN

Health-related Quality of Life in Patients on Anticoagulants

NCT03134911

Atrial Fibrillation

COMPLETED

FLorida Puerto Rico Atrial Fibrillation Stroke Study (FLiPER-AF)

NCT03627806

Atrial Fibrillation

COMPLETED

Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation

NCT00863213

Atrial Fibrillation

COMPLETED PHASE4

Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2

NCT02488421

Non-valvular Atrial Fibrillation

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anticoagulation, Blood Thinners , Atrial Fibrillation, Bleeding, Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

In patients

No interventions assigned to this group

Out patients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (≥18 years old)
* Patients diagnosed with Non-valvular atrial fibrillation (NVAF) any time prior to the inclusion date (prevalent or incident patients)
* Patients treated or not treated with an antithrombotic therapy
* Treated patients should have begun treatment prior to the inclusion visit
* Patients attending Internal Medicine departments, either for a hospital appointment (outpatients) or hospitalization (inpatients) for any reason)
* Patients which signed the informed consent

Exclusion Criteria

* Patients diagnosed with valvular atrial fibrillation any time in their medical records
* Patients with anticoagulant treatment prescribed for venous thromboembolic disease any time prior to the inclusion date
* Patients which participated in any clinical trial with anticoagulant and/or antiplatelet agents in the previous six months
* Patients incapable of giving their informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No